Walgreens Boots Alliance (NASDAQ:WBA - Free Report) had its price target lowered by UBS Group from $22.00 to $17.00 in a report released on Monday, Benzinga reports. UBS Group currently has a neutral rating on the pharmacy operator's stock.
Other research analysts have also recently issued reports about the company. Evercore ISI dropped their target price on Walgreens Boots Alliance from $18.00 to $17.00 and set an in-line rating on the stock in a research report on Monday, June 3rd. Morgan Stanley decreased their price objective on Walgreens Boots Alliance from $16.00 to $13.00 and set an underweight rating on the stock in a research note on Friday, May 31st. TD Cowen decreased their price objective on Walgreens Boots Alliance from $37.00 to $35.00 and set a buy rating on the stock in a research note on Wednesday, April 3rd. Bank of America decreased their price objective on Walgreens Boots Alliance from $23.00 to $22.00 and set an underperform rating on the stock in a research note on Tuesday, March 26th. Finally, Truist Financial reaffirmed a hold rating and issued a $25.00 price objective on shares of Walgreens Boots Alliance in a research note on Monday, April 1st. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus price target of $23.07.
Read Our Latest Analysis on Walgreens Boots Alliance
Walgreens Boots Alliance Stock Performance
Shares of Walgreens Boots Alliance stock traded down $0.06 during trading on Monday, hitting $15.91. 13,629,601 shares of the company's stock traded hands, compared to its average volume of 13,124,970. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.66 and a quick ratio of 0.32. Walgreens Boots Alliance has a 1 year low of $14.62 and a 1 year high of $31.88. The stock has a market capitalization of $13.73 billion, a P/E ratio of -2.27, a PEG ratio of 0.99 and a beta of 0.78. The business has a 50-day simple moving average of $16.80 and a 200-day simple moving average of $20.41.
Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) last announced its earnings results on Thursday, March 28th. The pharmacy operator reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.38. The business had revenue of $37.05 billion for the quarter, compared to analysts' expectations of $35.86 billion. Walgreens Boots Alliance had a positive return on equity of 12.11% and a negative net margin of 4.18%. The business's revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the firm posted $1.16 earnings per share. As a group, analysts forecast that Walgreens Boots Alliance will post 3.21 EPS for the current year.
Walgreens Boots Alliance Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 21st were paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 6.29%. The ex-dividend date was Monday, May 20th. Walgreens Boots Alliance's payout ratio is -14.29%.
Insiders Place Their Bets
In related news, CFO Manmohan Mahajan bought 6,000 shares of the company's stock in a transaction dated Tuesday, April 2nd. The stock was purchased at an average price of $19.38 per share, for a total transaction of $116,280.00. Following the acquisition, the chief financial officer now owns 166,969 shares in the company, valued at $3,235,859.22. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Manmohan Mahajan bought 6,000 shares of the company's stock in a transaction dated Tuesday, April 2nd. The stock was purchased at an average price of $19.38 per share, for a total transaction of $116,280.00. Following the acquisition, the chief financial officer now owns 166,969 shares in the company, valued at $3,235,859.22. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Inderpal S. Bhandari acquired 3,000 shares of the company's stock in a transaction that occurred on Thursday, April 11th. The shares were acquired at an average price of $18.05 per share, with a total value of $54,150.00. Following the acquisition, the director now owns 3,000 shares in the company, valued at $54,150. The disclosure for this purchase can be found here. Corporate insiders own 17.40% of the company's stock.
Institutional Investors Weigh In On Walgreens Boots Alliance
Several hedge funds have recently made changes to their positions in the company. Dark Forest Capital Management LP raised its position in shares of Walgreens Boots Alliance by 6.5% in the 3rd quarter. Dark Forest Capital Management LP now owns 29,409 shares of the pharmacy operator's stock worth $654,000 after acquiring an additional 1,804 shares in the last quarter. Cary Street Partners Investment Advisory LLC raised its position in shares of Walgreens Boots Alliance by 21.6% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 23,417 shares of the pharmacy operator's stock worth $521,000 after acquiring an additional 4,166 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Walgreens Boots Alliance during the 3rd quarter valued at about $5,494,000. Natixis Advisors L.P. increased its position in Walgreens Boots Alliance by 268.4% during the 3rd quarter. Natixis Advisors L.P. now owns 184,722 shares of the pharmacy operator's stock valued at $4,108,000 after buying an additional 134,587 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its position in Walgreens Boots Alliance by 30.5% during the 3rd quarter. Parkside Financial Bank & Trust now owns 3,579 shares of the pharmacy operator's stock valued at $80,000 after buying an additional 837 shares in the last quarter. 58.59% of the stock is currently owned by hedge funds and other institutional investors.
About Walgreens Boots Alliance
(Get Free Report)
Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.
Featured Stories
- Five stocks we like better than Walgreens Boots Alliance
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- The Top 3 Sectors Poised For Growth This Summer
- How to Invest in Small Cap Stocks
- U.S. Steel Stock: Betting on EPS Cut and Merger Uncertainty?
- What is the NASDAQ Stock Exchange?
- GitLab Stock: Pioneering the AI-Powered DevSecOps Platform
→ The asset beating inflation by 4x (From Colonial Metals) (Ad)
Should you invest $1,000 in Walgreens Boots Alliance right now?
Before you consider Walgreens Boots Alliance, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Walgreens Boots Alliance wasn't on the list.
While Walgreens Boots Alliance currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
13 Stocks Institutional Investors Won't Stop Buying
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
